Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Horizon Discovery, Cartana, ProteoGenix, More

Horizon Discovery FFPE, Liquid Biopsy OncoSpan Reference Standards

Horizon Discovery has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays. The company's OncoSpan range now includes formalin-fixed, paraffin-embedded and cell-free DNA formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its genomic DNA format. Its cfDNA format offers more than 380 variants and 152 genes to help standardize liquid biopsy testing.

These cell line-derived reference standards closely mimic patient samples and offer an unlimited and reproducible resource to help ensure consistency during the establishment and validation of diagnostic assays, Horizon said. All three formats are delivered with batch-specific, next-generation sequencing data, orthogonally validated by droplet digital PCR, to allow researchers to further validate their analysis pipeline.


Cartana In Situ Sequencing Reagent Kits

Cartana has launched a new range of in situ sequencing reagent kits designed to increase the efficiency and enable ISS on virtually any tissue sample. The new kits contain improved probing and sequencing technologies and come with easy-to-follow protocols for library preparation and sequencing. The HS Library Preparation Kit is used to probe directly up to 600 RNA targets in either fresh/fixed frozen or FFPE samples without the need for cDNA synthesis, and generates barcoded in situ sequencing libraries with higher efficiency compared to a previous cDNA-based library preparation approach, initially published in 2013, Cartana said. Furthermore, the new ISS kit sequences the barcodes in the libraries directly in situ, with enhanced signal-to-noise ratio and specificity compared to the previous state-of-the-art ISS technology. The new kit contains six sequencing cycles and decodes up to 600 barcodes using a standard fluorescent microscope.


ProteoGenix Human Immune COVID-19 Library

ProteoGenix has launched a Human Immune COVID-19 Library to facilitate the discovery of antibodies against SARS-CoV-2. Created using blood samples from dozens of recovered COVID-19 patients, the library is adapted for screening with phage display and features 1.2 x 1010 different clones. The phage display screening technology coupled with the library's diversity is expected to speed the discovery of antibodies with the strongest affinity, specificity, and viral blocking activity, the company said. ProteoGenix said that it also offers a broad diversity of ready-made SARS-CoV-2 antigens, as well as custom antigen development services. Within eight weeks, clients can receive three to 10 unique and royalty-free antibody sequences with optimal affinity.


For more new products and services, please visit the New Products page on our website.